{"id":"W4281654580","doi":"10.1200/jco.2022.40.16_suppl.tps7595","title":"TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pfizer (Canada); Trillium Therapeutics (Canada)","funders":"","keywords":"CD47; Medicine; Cancer research; Phagocytosis; Lymphoma; Immune system; CD20; Cancer; Immunology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007927903,0.00138431,0.00109813,0.0005027376,0.0004005886,0.001193278,0.0006832816,0.001381288,0.005231685],"category_scores_gemma":[0.0003829653,0.0004760444,0.000888239,0.0004237795,0.0006150467,0.0008073651,0.0003969462,0.003411727,0.001385821],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009678164,"about_ca_system_score_gemma":0.0009604325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000756306,"about_ca_topic_score_gemma":0.002660865,"domain_scores_codex":[0.9997869,0.00006029068,0.000009368417,0.00004645743,0.00002954147,0.00006737243],"domain_scores_gemma":[0.9997274,0.00002060081,0.00004278589,0.0000192578,0.00001724815,0.0001726837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3398022,0.07866933,0.00889976,0.001562403,0.001755373,0.0007899599,0.0007082495,0.006569637,0.1600816,0.001726414,0.02672714,0.3727081],"study_design_scores_gemma":[0.5349541,0.4085154,0.0205604,0.0001136332,0.000641305,0.001259387,0.0001453586,0.003645028,0.01038531,0.001103896,0.01858284,0.00009334845],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839028,0.004068341,0.0010176,0.001325989,0.0002583802,0.002208284,0.001893922,0.0003251717,0.004999547],"genre_scores_gemma":[0.9753664,0.002950272,0.002144284,0.002904139,0.0002068017,0.003115342,0.005156696,0.0000957638,0.008060274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005231685,"threshold_uncertainty_score":0.01750171,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0543840696318726,"score_gpt":0.3744468384151424,"score_spread":0.3200627687832698,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}